Ghent University Academic Bibliography

Advanced

FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases

Rudi Dierckx UGent, Alex Maes, Marc Peeters UGent and Christophe Van De Wiele UGent (2009) QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 53(3). p.336-342
abstract
Local ablative therapies and loco-regional therapies are being increasingly used for the purpose of providing local control of primary liver tumors and liver metastases while sparing normal liver tissue. in this manuscript, literature on the use of fluorodeoxyglucose positron emission tomography (FDG PET) to monitor local and locoregional treatment for hepatocellular carcinoma (HCC) and liver metastases, mainly limited to radio,frequency ablation (RFA) and selective internal radiation therapy (SIRT) is reviewed. Available data obtained primarily in secondary liver tumors and to a lesser extent in HCC support the notion that FDG PET performed early after RFA provides additional information about the efficacy of local tumor ablation by differentiating post-treatment changes from residual or recurrent malignant tumor. In addition, FDG PET was shown to have an added value for the detection of tumor recurrence. Thus, FDG PET imaging may not only improve treatment evaluation but also provide an opportunity for early re-intervention following RFA. Potential problems that might occur when using FDG PET for the purpose of evaluation of RFA are false negative results due to partial volume effect when dealing with small lesions (<1 cm) or due to diabetes and false positive results due to abscess formation. Larger studies are warranted to confirm these promising results. With regard to SIRT, several studies, almost exclusively performed in patients suffering from liver metastases, have addressed the feasibility of using FDG PET for the assessment and quantification of metabolic response of SIRT with Y-90-microspheres. These studies consistently show that traditional morphological imaging, computed tomography/magnetic resonance imaging, is insensitive in monitoring response, owing to the presence of necrosis, edema, hemorrhage and cystic changes, when compared to metabolic imaging. Thus, in view of the lack of reliability of tumor markers and/or the potential for delineating the presence of extra-hepatic metastatic cancers in these patients, when confirmed by additional studies, FDG PET may prove to be an excellent adjunct for assessing response following SIRT of liver metastases.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
journal title
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Q. J. Nucl. Med. Mol. Imag.
volume
53
issue
3
pages
336 - 342
Web of Science type
Review
Web of Science id
000268849500009
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
2.877 (2009)
JCR rank
23/104 (2009)
JCR quartile
1 (2009)
ISSN
1824-4661
language
English
UGent publication?
yes
classification
A1
id
810548
handle
http://hdl.handle.net/1854/LU-810548
date created
2009-12-14 13:00:44
date last changed
2009-12-15 15:56:38
@article{810548,
  abstract     = {Local ablative therapies and loco-regional therapies are being increasingly used for the purpose of providing local control of primary liver tumors and liver metastases while sparing normal liver tissue. in this manuscript, literature on the use of fluorodeoxyglucose positron emission tomography (FDG PET) to monitor local and locoregional treatment for hepatocellular carcinoma (HCC) and liver metastases, mainly limited to radio,frequency ablation (RFA) and selective internal radiation therapy (SIRT) is reviewed. Available data obtained primarily in secondary liver tumors and to a lesser extent in HCC support the notion that FDG PET performed early after RFA provides additional information about the efficacy of local tumor ablation by differentiating post-treatment changes from residual or recurrent malignant tumor. In addition, FDG PET was shown to have an added value for the detection of tumor recurrence. Thus, FDG PET imaging may not only improve treatment evaluation but also provide an opportunity for early re-intervention following RFA. Potential problems that might occur when using FDG PET for the purpose of evaluation of RFA are false negative results due to partial volume effect when dealing with small lesions ({\textlangle}1 cm) or due to diabetes and false positive results due to abscess formation. Larger studies are warranted to confirm these promising results. With regard to SIRT, several studies, almost exclusively performed in patients suffering from liver metastases, have addressed the feasibility of using FDG PET for the assessment and quantification of metabolic response of SIRT with Y-90-microspheres. These studies consistently show that traditional morphological imaging, computed tomography/magnetic resonance imaging, is insensitive in monitoring response, owing to the presence of necrosis, edema, hemorrhage and cystic changes, when compared to metabolic imaging. Thus, in view of the lack of reliability of tumor markers and/or the potential for delineating the presence of extra-hepatic metastatic cancers in these patients, when confirmed by additional studies, FDG PET may prove to be an excellent adjunct for assessing response following SIRT of liver metastases.},
  author       = {Dierckx, Rudi and Maes, Alex and Peeters, Marc and Van De Wiele, Christophe},
  issn         = {1824-4661},
  journal      = {QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  language     = {eng},
  number       = {3},
  pages        = {336--342},
  title        = {FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases},
  volume       = {53},
  year         = {2009},
}

Chicago
Dierckx, Rudi, Alex Maes, Marc Peeters, and Christophe Van De Wiele. 2009. “FDG PET for Monitoring Response to Local and Locoregional Therapy in HCC and Liver Metastases.” Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 (3): 336–342.
APA
Dierckx, R., Maes, A., Peeters, M., & Van De Wiele, C. (2009). FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 53(3), 336–342.
Vancouver
1.
Dierckx R, Maes A, Peeters M, Van De Wiele C. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;53(3):336–42.
MLA
Dierckx, Rudi, Alex Maes, Marc Peeters, et al. “FDG PET for Monitoring Response to Local and Locoregional Therapy in HCC and Liver Metastases.” QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 53.3 (2009): 336–342. Print.